Scientists from Kings College London examined the medical records of 2,026 first-time psychotic patients treated in London between 2006 and 2013. They looked at the date when the patients were admitted in hospital for first treatment, and researched any information regarding potential drug abuse.
For the next five years following treatment, they took a note of every hospital readmission for psychosis, and assessed the number of unique anti-psychosis drugs prescribed to each patient.
50% more risk for users
Within one month of the first hospitalisation and treatment, more than 46% of patients had used cannabis at least one time. This was particularly the case amongst single men aged between 16 and 25. The researchers’ analysis suggests that cannabis users were then 50% more likely to be readmitted into hospital for another psychosis episode than non-users, in the five years after receiving initial treatment.
Amongst hospitalised psychosis patients, the length of the hospital stay was significantly longer if they has used cannabis. It lasted 35 days in average, compared to 21 days for those who did not use cannabis.
More anti-psychosis drugs
The researchers also discovered that cannabis users were often prescribed more psychosis medicine than their counterparts during the five years of the follow-up, suggesting that first intention drugs failed more often than not to help such patients. In particular, the cannabis users were more frequently given clozapine, a powerful drug commonly used for schizophrenia.
Although they still cannot explain how cannabis affects the brain of psychotic patients and how it may interfere with treatments, the study’s authors note that it does lead to a worse outcome. These results are therefore a clear indication that people with psychotic disorders should avoid cannabis.